[HTML][HTML] Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update

R Roskoski Jr - Pharmacological research, 2023 - Elsevier
Owing to the dysregulation of protein kinase activity in many diseases including cancer, this
enzyme family has become one of the most important drug targets in the 21 st century. There …

Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update

R Roskoski Jr - Pharmacological research, 2020 - Elsevier
Because genetic alterations including mutations, overexpression, translocations, and
dysregulation of protein kinases are involved in the pathogenesis of many illnesses, this …

Bone metastasis: mechanisms, therapies, and biomarkers

P Clézardin, R Coleman, M Puppo… - Physiological …, 2021 - journals.physiology.org
Skeletal metastases are frequent complications of many cancers, causing bone
complications (fractures, bone pain, disability) that negatively affect the patient's quality of …

Properties of FDA-approved small molecule protein kinase inhibitors

R Roskoski Jr - Pharmacological research, 2019 - Elsevier
Because mutations, overexpression, and dysregulation of protein kinases play essential
roles in the pathogenesis of many illnesses, this enzyme family has become one of the most …

Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update

R Roskoski Jr - Pharmacological research, 2021 - Elsevier
Owing to the dysregulation of protein kinase activity in many diseases including cancer, the
protein kinase enzyme family has become one of the most important drug targets in the 21st …

Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers

R Roskoski Jr - Pharmacological research, 2019 - Elsevier
The EGFR family is among the most investigated receptor protein-tyrosine kinase groups
owing to its general role in signal transduction and in oncogenesis. This family consists of …

[HTML][HTML] Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update

R Roskoski Jr - Pharmacological research, 2024 - Elsevier
Owing to the dysregulation of protein kinase activity in many diseases including cancer, this
enzyme family has become one of the most important drug targets in the 21 st century. There …

Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs

R Roskoski Jr - Pharmacological research, 2019 - Elsevier
Cyclins and cyclin-dependent protein kinases (CDKs) are important proteins that are
required for the regulation and expression of the large number of components necessary for …

Protein–ligand binding with the coarse-grained Martini model

PCT Souza, S Thallmair, P Conflitti… - Nature …, 2020 - nature.com
The detailed understanding of the binding of small molecules to proteins is the key for the
development of novel drugs or to increase the acceptance of substrates by enzymes …

Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors

SA Kovács, JT Fekete, B Győrffy - Acta Pharmacologica Sinica, 2023 - nature.com
Immune-checkpoint inhibitors show promising effects in the treatment of multiple tumor
types. Biomarkers are biological indicators used to select patients for a systemic anticancer …